English Spanish Chinese Russian German French Japanese Hindi Telugu Tamil

Arquivos na pesquisa do câncer

  • ISSN: 2254-6081
  • Índice h do diário: 13
  • Pontuação de citação de diário: 3.58
  • Fator de impacto do periódico: 3.12
Indexado em
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Google Scholar
  • Laboratórios secretos do mecanismo de pesquisa
Veja mais
Compartilhe esta página

Abstrato

Inhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer

Aurelio B Castrellon, Steven M Nguyen and Luis E Raez

Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ threonine kinases that play a key role in regulating cell cycle progression. In this review, we discuss the currently approved and under investigation CDK 4/6 inhibitors, in addition to their preclinical data and clinical trials that demonstrated their benefit in the treatment of HR+ breast cancer.